Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why

Zacks01-12

Shares of Amicus Therapeutics, Inc. FOLD have rallied 27.9% in the past three months compared with the industry’s increase of 10.7%. In late September 2023, the FDA approved Pombiliti + Opfolda, a two...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2403229380?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41","is_english":true,"pubTime":"2024-01-12 22:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2403229380","market":"us","top_or_hot":-1,"title":"Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why","media":"Zacks","content":"<div>\n<p>Shares of Amicus Therapeutics, Inc. FOLD have rallied 27.9% in the past three months compared with the industry’s increase of 10.7%.\nIn late September 2023, the FDA approved Pombiliti + Opfolda, a two...</p>\n\n<a href=\"https://finance.yahoo.com/news/amicus-fold-stock-rises-more-143100573.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmicus (FOLD) Stock Rises More Than 25% in 3 Months: Here's Why\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-01-12 22:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/amicus-fold-stock-rises-more-143100573.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Amicus Therapeutics, Inc. FOLD have rallied 27.9% in the past three months compared with the industry’s increase of 10.7%.\nIn late September 2023, the FDA approved Pombiliti + Opfolda, a two...</p>\n\n<a href=\"https://finance.yahoo.com/news/amicus-fold-stock-rises-more-143100573.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065169927.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/amicus-fold-stock-rises-more-143100573.html","article_id":"2403229380","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/VTpWEp9iphTX3xsYcMogbg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ca9d72216d7bb42fc496430c3df29b41"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2403229380","pubTimestamp":1705069860,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Amicus Therapeutics, Inc. FOLD have rallied 27.9% in the past three months compared with the industry’s increase of 10.7%.In late September 2023, the FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease  in adults who weigh more than 40 kg and are not improving on their current enzyme replacement therapy.The approval for Pombiliti + Opfolda in the United States is a huge boost and provides a significant commercial opportunity for Amicus in 2024. This could have been one of the factors driving the stock’s rise in the said time frame.Earlier in 2023, Pombiliti + Opfolda was approved in Europe, including the United Kingdom, for treating LOPD in adults.Amicus’ lead drug, Galafold , is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has shown solid uptake since its launch.CytomX Therapeutics beat estimates in three of the last four quarters while missing the same","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","CTMX":"CytomX","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","FOLD":"爱美医疗","BK4139":"生物科技","FRLN":"Freeline Therapeutics Holdings plc","PBYI":"Puma Biotechnology Inc"},"translate_title":"Amicus（FOLD）股票在3个月内上涨超过25%：原因如下","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTMX":1,"FOLD":1,"FRLN":1,"PBYI":1},"content_text":"Shares of Amicus Therapeutics, Inc. FOLD have rallied 27.9% in the past three months compared with the industry’s increase of 10.7%.\nIn late September 2023, the FDA approved Pombiliti + Opfolda, a two-component therapy for treating late-onset Pompe disease (LOPD) in adults who weigh more than 40 kg and are not improving on their current enzyme replacement therapy.\nThe approval for Pombiliti + Opfolda in the United States is a huge boost and provides a significant commercial opportunity for Amicus in 2024. This could have been one of the factors driving the stock’s rise in the said time frame.\nEarlier in 2023, Pombiliti + Opfolda was approved in Europe, including the United Kingdom, for treating LOPD in adults.\nImage Source: Zacks Investment Research\nAmicus’ lead drug, Galafold (migalastat), is the first and only approved oral medicine for patients living with Fabry disease, having amenable genetic variants. The drug has shown solid uptake since its launch.\nSales of Galafold have been rising consistently over the past years. In the first nine months of 2023, the drug generated sales worth $281.2 million, increasing 16.6% on a year-over-year basis.\nEarlier this month, Amicus announced encouraging preliminary results for the fourth quarter of 2023. The company also provided a strategic outlook for 2024.\nFor the fourth quarter of 2023, preliminary total revenues were approximately $115.1 million. The Zacks Consensus Estimate for fourth-quarter revenues stands at $110.6 million.\nGalafold net sales were around $106.6 million in the fourth quarter.\nNewly approved product, Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat), generated sales of roughly $8.5 million in the fourth quarter of 2023.\nAmicus aims to deliver Galafold revenue growth of 11-16% at CER in 2024. The company is also looking to ensure the successful global launch of Pombiliti + Opfolda for Pompe disease. Launches are currently underway in the United States, EU and United Kingdom.\nAlso, the company targets to achieve full-year profitability on a non-GAAP basis in 2024.\nThe strong uptake of Galafold and the successful launch of Pombiliti + Opfolda should continue the upward momentum for Amicus in 2024, as both Fabry disease and Pompe disease are rare diseases.\n\nAmicus Therapeutics, Inc. Price\n  \nAmicus Therapeutics, Inc. price | Amicus Therapeutics, Inc. Quote\n\nZacks Rank & Stocks to Consider\nAmicus currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the healthcare sector are CytomX Therapeutics, Inc. CTMX, Freeline Therapeutics Holdings plc FRLN and Puma Biotechnology, Inc. PBYI, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 60 days, estimates for CytomX Therapeutics’ 2024 loss per share have narrowed from 22 cents to 6 cents. In the past year, shares of CTMX have plunged 40.9%.\nCytomX Therapeutics beat estimates in three of the last four quarters while missing the same on the remaining occasion. CTMX delivered a four-quarter earnings surprise of 45.44%, on average.\nIn the past 60 days, estimates for Freeline Therapeutics’ 2024 loss per share have narrowed from 35 cents to 15 cents. In the past year, shares of FRLN have declined 17.5%.\nEarnings of Freeline Therapeutics beat estimates in each of the last three quarters. FRLN delivered a four-quarter average earnings surprise of 67.17%.\nIn the past 60 days, estimates for Puma Biotechnology’s 2024 earnings per share have improved from 62 cents to 69 cents. In the past year, shares of PBYI have lost 5.4%.\nEarnings of Puma Biotechnology beat estimates in three of the last four quarters while missing the same on the remaining occasion. PBYI delivered a four-quarter average earnings surprise of 76.55%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAmicus Therapeutics, Inc. (FOLD) : Free Stock Analysis Report\nPuma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nFreeline Therapeutics Holdings PLC Sponsored ADR (FRLN) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2403229380"}